ROS-Responsive PPS Microparticles for Controlled Curcumin Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current delivery systems for hydrophobic drugs like curcumin face challenges due to their extreme hydrophobicity, leading to poor aqueous solubility and rapid metabolism, and conventional microparticles degrade non-specifically, causing uncontrolled drug release and local inflammation in treating inflammatory diseases such as peripheral arterial disease (PAD) associated with oxidative stress.
Innovation Solution
Development of biodegradable, ROS-responsive poly(propylene sulfide) (PPS) microparticles that transition from hydrophobic to hydrophilic upon exposure to reactive oxygen species (ROS), enabling controlled, 'on-demand' release of hydrophobic drugs like curcumin, reducing oxidative stress and inflammation, and providing a local depot for sustained drug delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional PLGA-based microparticles are used for drug delivery, then sustained drug release is achieved, but uncontrolled drug release and local inflammation occur due to non-specific hydrolysis and autocatalytic degradation
Solution Approach 1:
The patent changes the degradation mechanism parameter from non-specific hydrolysis to ROS-triggered oxidation. The PPS microparticles are designed to remain stable under normal physiological conditions but undergo controlled degradation when exposed to elevated ROS levels at inflammatory sites, achieving both sustained release and controlled release profiles
Solution Approach 2:
The patent converts the harmful effect of ROS (oxidative stress causing inflammation) into a beneficial trigger for drug release. The ROS that normally cause tissue damage are now utilized to activate the degradation of PPS microparticles and release anti-inflammatory drugs precisely where needed, turning a pathological factor into a therapeutic advantage
2Quantity of substance
If curcumin is administered systemically, then anti-inflammatory effects are achieved, but poor aqueous solubility and rapid metabolism reduce bioavailability
Solution Approach 1:
The patent uses microparticle encapsulation to protect curcumin from metabolism and improve its solubility. The PPS microparticle shell provides a protective barrier that prevents rapid metabolism while the controlled degradation mechanism ensures sustained release of curcumin at the target site, significantly improving bioavailability
Solution Approach 2:
The PPS microparticles act as an intermediary carrier that solves the solubility problem. The microparticles provide an interface between the hydrophobic curcumin and the aqueous physiological environment, enabling curcumin to be delivered systemically with improved solubility and stability while maintaining its anti-inflammatory efficacy
3Reliability
If PPS microparticles are used for drug delivery, then ROS-responsive controlled release is achieved, but the hydrophobicity of PPS may limit drug encapsulation efficiency
Solution Approach 1:
The patent exploits the hydrophobic nature of PPS as a beneficial feature for encapsulating hydrophobic drugs like curcumin. The hydrophobic polymer matrix provides favorable interactions with hydrophobic drug molecules, enhancing encapsulation efficiency. The parameter change occurs in the polymer's hydrophilicity rather than its hydrophobicity, with ROS triggering a transition from hydrophobic to hydrophilic state for controlled release
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PPS microparticles effectively modulate drug release based on ROS levels, reducing oxidative stress and inflammation, improving bioavailability and therapeutic efficacy of curcumin, while avoiding acidification of the local environment and enhancing cell survival, thereby improving treatment outcomes for PAD.
Implementation Method 1
exposure of PPS to ROS causes it to transition to a hydrophilic form, which triggers gradual particle swelling/dissolution and 'on-demand' drug release
Implementation Method 2
The reaction of PPS with ROS that triggers this phase change from hydrophobic to hydrophilic gives PPS 'ROS sponge' function, which may also give the microparticles an inherent ability to help to 'detoxify' oxidative stress
Data Source
AI summary
A reactive oxygen species savaging emulsion; the emulsion comprising an injectable pharmaceutically acceptable composition and a polymeric poly(propylene sulfide) microsphere for targeted delivery to a site with elevated reactive oxygen species. In embodiments of the present invention, the microsphere is loaded with a biologically active agent.